1. Home
  2. ADV vs RLMD Comparison

ADV vs RLMD Comparison

Compare ADV & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Advantage Solutions Inc.

ADV

Advantage Solutions Inc.

N/A

Current Price

$32.89

Market Cap

523.2M

ML Signal

N/A

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

N/A

Current Price

$4.81

Market Cap

524.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ADV
RLMD
Founded
1987
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
523.2M
524.9M
IPO Year
2019
2012

Fundamental Metrics

Financial Performance
Metric
ADV
RLMD
Price
$32.89
$4.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$45.83
$12.40
AVG Volume (30 Days)
108.2K
1.6M
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
45.28
EPS
N/A
N/A
Revenue
$3,542,642,000.00
$13,070.00
Revenue This Year
$0.63
N/A
Revenue Next Year
$0.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
154.83
52 Week Low
$0.49
$0.59
52 Week High
$47.45
$8.00

Technical Indicators

Market Signals
Indicator
ADV
RLMD
Relative Strength Index (RSI) 45.19 36.91
Support Level $0.78 $4.06
Resistance Level $44.60 $5.05
Average True Range (ATR) 3.60 0.31
MACD -0.42 -0.01
Stochastic Oscillator 48.66 36.33

Price Performance

Historical Comparison
ADV
RLMD

About ADV Advantage Solutions Inc.

Advantage Solutions Inc provides outsourced sales, marketing, merchandising, sampling, and retailer support services to consumer packaged goods manufacturers and retailers across North America. Its services are designed to support distribution, retail execution, shopper engagement, and private brand development across both physical and digital commerce environments. The company serves various clients across grocery, mass, club, retail pharmacy, convenience, and other channels. It operates through three reportable segments: Branded Services, Experiential Services, and Retailer Services. The majority of the revenue is derived from the Experiential Services segment, which provides in-store and digital sampling programs, demonstrations, and experiential events for manufacturers and retailers.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: